

REMARKS

DRAWINGS

The Notice of Allowability mailed November 19, 2004 indicates that Corrected Drawings as “replacement sheets” must be submitted, including changes required by attached to paper No. 8 (March 27, 2003). the Notice of Draftperson’s Patent Drawing Review. The Notice of Draftperson’s Patent Drawing Review indicates that Figures 3, 4, 5, and 7 is not accepted, due to overlapping letters in the drawings. Corrected Figures 3A, 3B, 4A, 4B, 5, and 7 are submitted on a total of 4 “Replacement Sheets”. No new matter is entered by way of this submission, and Applicant submits that the drawings are compliant with 37 C.F.R. § 1.84.

Replacement of the corresponding Figures 3, 4, 5, and 7 with the attached corrected Figures 3A, 3B, 4A, 4B, 5, and 7 submitted on the total of 4 “Replacement Sheets, is respectfully requested.

CLAIM AMENDMENTS

Claims 1, 2, 3, 5, 6, 10 and 19 to 23 have been allowed. Claims 1, 19 and 20 have been rewritten in order to correct typographical errors found in the Examiner’s Amendment mailed November 19, 2004. In a telephone interview between the undersigned and the Examiner on February 18, 2005, agreement was reached that Applicants will correct these typographical errors by way of rule 312 (37 C.F.R. § 1.312) amendment.

The claim prior to the present amendment is shown as including the Examiner’s amendment. That is, as amended by the Examiner, the first line of claims 1, 19, and 20 would respectively read:

1. “A method for detecting gabapentinoid activity in test a compound comprising ...”
19. “A method for detecting gabapentinoid activity in test a compound comprising ...”
20. “A method for detecting gabapentinoid activity in target a compound comprising ...”

Clearly, and as agreed to by the Examiner on the February 18, 2005 telephone interview,

the above insertions of "test" in claims 1 and 19, and of "target" in claim 20 constitutes a minor typographical error and is readily corrected by the amendments submitted in this paper, the relevant portion of the amended claims shown below:

1. A method for detecting gabapentinoid activity in ~~test~~ a test compound comprising the steps of:

19. A method for detecting gabapentinoid activity in ~~test~~ a test compound comprising the steps of:

20. (Previously Added) A method for detecting gabapentinoid activity in ~~target~~ a target compound comprising the step of:

Accordingly, Applicants respectfully request entry of each of the claim amendments submitted in this paper prior to issuance of this application.

The Commissioner is authorized to charge any fee or credit any over payment in connection with this communication to our Deposit Account No. 23-0455.

Respectfully submitted,

Date: February 22, 2005

By: Mehdi Ganjeizadeh
Mehdi Ganjeizadeh
Registration No. 47,585
Warner-Lambert Company LLC
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-3831
Facsimile: (734) 622-2928